6 analyst cuts: Ascendis downgraded on FDA report, shares plunge Finances April 4, 2023 [ad_1] © Reuters. By Davit KirakosyanInvesting.com — Right here is your every day Professional Recap of the most important analyst…
Ascendis Pharma prices $500.0M convertible senior notes offering Markets March 25, 2022 [ad_1] Ascendis Pharma (NASDAQ:ASND) has priced of its providing of $500M of two.25% convertible senior notes due 2028 in a…
